Clinical Trials Logo

Advanced Tumors clinical trials

View clinical trials related to Advanced Tumors.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06314087 Not yet recruiting - Advanced Tumors Clinical Trials

iTAPVR Study - Phase II Randomized Study

Start date: March 2024
Phase: Phase 2
Study type: Interventional

In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy

NCT ID: NCT05213767 Not yet recruiting - Advanced Tumors Clinical Trials

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Start date: February 2022
Phase: Phase 1
Study type: Interventional

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB2916 injection in patients with advanced tumors, and to initially evaluate the antitumor efficacy of TQB2916 injection.

NCT ID: NCT04151810 Not yet recruiting - Advanced Tumors Clinical Trials

Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors

Start date: December 30, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical trials.